Large Australian Trial Finds Pneumococcal Vaccine Ineffective for Cardiovascular Protection
Key Insights
A randomized controlled trial of 4,725 Australian adults found that the 23-valent pneumococcal polysaccharide vaccine (PPSV23) did not significantly reduce fatal and nonfatal acute coronary syndrome or ischemic stroke compared to placebo over 7 years of follow-up.
The study enrolled community-dwelling adults aged 55-60 with at least two cardiovascular risk factors but no prior cardiovascular events, tracking outcomes through electronic health records across six Australian centers.
Despite previous observational studies suggesting cardiovascular benefits from pneumococcal vaccination, this randomized trial showed no statistically significant difference in primary outcomes between vaccine and placebo groups.
A large randomized controlled trial conducted across Australia has found that the 23-valent pneumococcal polysaccharide vaccine (PPSV23) does not provide cardiovascular protection in adults at increased risk for heart disease. The study, published in JAMA Cardiology, challenges previous observational research suggesting pneumococcal vaccination might reduce cardiovascular events.
Study Design and Population
The double-blind, placebo-controlled trial enrolled 4,725 community-dwelling adults aged 55 to 60 years across six Australian study centers between 2016 and 2017. Participants had no prior cardiovascular events but carried at least two risk factors for cardiovascular disease, including obesity, hypertension, or hypercholesterolemia. The mean age of participants was 58.0 years.
Participants were randomly assigned to receive either PPSV23 (Pneumovax (search); Merck & Co) or saline placebo, with neither patients nor clinicians aware of the treatment allocation. The study tracked participants for an average of 7 years through electronic health records covering hospital admissions, emergency visits, and mortality data.
Primary Outcomes Show No Benefit
The primary composite endpoint measured fatal and nonfatal acute coronary syndrome and ischemic stroke. Results showed no statistically significant difference between treatment groups, with 58 events occurring in the PPSV23 group (2,366 participants) compared to 64 events in the placebo group (2,357 participants). This translated to a hazard ratio of 0.90 (95% confidence interval, 0.63-1.28; P = .57).
Exploratory analyses examining all-cause mortality, all-cause hospital presentations, and cardiovascular-related hospital procedures also revealed no significant differences between groups.
Statistical Power Limitations
The investigators acknowledged that the study was underpowered due to a lower-than-expected cardiovascular event rate. This limitation reduced the trial's ability to detect modest protective effects if they exist. The researchers noted that larger sample sizes would be necessary in future randomized studies to definitively answer questions about pneumococcal vaccination's cardiovascular benefits.
Clinical Context and Implications
Previous research had suggested that up to 30% of patients hospitalized with invasive pneumococcal disease experience major adverse cardiovascular events, including new or worsening heart failure and myocardial infarction. Some studies indicated that pneumococcal vaccination might be cardioprotective, potentially reducing myocardial infarction risk and all-cause cardiovascular mortality through immune-mediated mechanisms affecting atherosclerosis.
However, this randomized trial data does not support using PPSV23 as a cardiovascular disease prevention strategy. The findings highlight important differences that may exist between pneumococcal vaccine types, as the United States uses both PPSV23, which utilizes a sugar component to stimulate immune response, and pneumococcal conjugate vaccines (PCVs), which use protein carriers.
Future Research Directions
The study authors emphasized that direct comparisons between different pneumococcal vaccines are essential for thoroughly understanding their potential cardiovascular protection. While PPSV23 remains an important tool for preventing pneumococcal infections in older adults and vulnerable populations, its role in cardiovascular protection appears limited based on this randomized evidence.
The trial represents one of the first large-scale randomized studies specifically examining PPSV23's cardiovascular effects, providing crucial evidence for clinical decision-making regarding vaccine use in cardiovascular disease prevention strategies.